Clinical trial
Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast…
NCT00006110 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006110 |
|---|---|
| Title | Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer |
| Official title | Nonrandomized Ph II Study of Multimodality Therapy for Stg IIB, IIIA/B, or Stg IV Breast Cancer w/4 Cycles of Adriamycin and Cytoxan (AC),Followed by 12 Weeks of Paclitaxel w/ or w/o Herceptin Followed by Local Therapy Followed by Wkly Herceptin or no Additional Therapy |
| Acronym | NRR |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, conventional surgery |
| Enrollment | 82 |
| Start date | Dec 1, 1998 |
| Primary completion | Mar 1, 2012 |
| Completion | Apr 1, 2013 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 31, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: